Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Nitin T. Telang"'
Autor:
Nitin T. Telang
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 22, p 14457 (2022)
In the multi-factorial etiology of organ-site cancers by suspect human chemical carcinogens, oncogenic virus, activation of RAS, Myc and HER-2 oncogenes, inactivation of TP53, RB and APC tumor suppressor genes represent early-occurring genetic events
Externí odkaz:
https://doaj.org/article/25a0364af1e045118ed54a056b5747b3
Autor:
Nitin T. Telang
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 9223 (2022)
The progression of the early stages of female breast and colon cancer to metastatic disease represents a major cause of mortality in women. Multi-drug chemotherapy and/or pathway selective targeted therapy are notable for their off-target effects and
Externí odkaz:
https://doaj.org/article/5efe93b3097a435ea713d0a03d14db3e
Autor:
Nitin T. Telang
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 9, p 4800 (2022)
The growth modulating effects of the ovarian steroid hormones 17β-estradiol (E2) and progesterone (PRG) on endocrine-responsive target tissues are well established. In hormone-receptor-positive breast cancer, E2 functions as a potent growth promoter
Externí odkaz:
https://doaj.org/article/cd6514e417b24f1ca1796944de6073cd
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1318 (2021)
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α progesterone receptor and human epidermal growth factor receptor-2. Treatment for this breast cancer subtype is restricted to multidrug chemotherapy and surv
Externí odkaz:
https://doaj.org/article/ed787f058c1e44e293e972f9a606b7b1
Publikováno v:
International Journal of Functional Nutrition. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a12acac257ab2a7eefbb17b45ff15d5
https://doi.org/10.3892/ijfn.2021.18
https://doi.org/10.3892/ijfn.2021.18
Abstract P4-13-04: Efficacy of dipsacus asperoides (DA) in a model for triple negative breast cancer
Publikováno v:
Cancer Research. 77:P4-13
Background: The triple negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α (ER-α), Progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). This molecular subtype responds only to conventiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b03f2bc77f28133ead21ffa6398f6867
https://doi.org/10.1158/1538-7445.sabcs16-p4-13-04
https://doi.org/10.1158/1538-7445.sabcs16-p4-13-04
Publikováno v:
Oncology Letters. 13:2477-2482
The Luminal A subtype of breast cancer expresses the estrogen receptor (ER)-α and progesterone receptor (PR), but not the human epidermal growth factor receptor (HER)-2 oncogene. This subtype of breast cancer responds to endocrine therapy involving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::170dc807848aa29d4dc08d8c3798caf1
https://doi.org/10.3892/ol.2017.5720
https://doi.org/10.3892/ol.2017.5720
Publikováno v:
Biomedical Reports.
Aromatase inhibitors (AIs) represent a treatment option for post-menopausal estrogen receptor-positive (ER(+)) breast cancer as monotherapy, or in combination with cyclin-dependent kinase 4/6 or mTOR inhibitors. Long-term treatment with these agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c7a0c90fb31a56db771913a98d98aa5
https://doi.org/10.3892/br.2019.1244
https://doi.org/10.3892/br.2019.1244
Publikováno v:
Experimental Colon Carcinogenesis ISBN: 9780429263781
Experimental Colon Carcinogenesis
Experimental Colon Carcinogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d1bade4da58eeef283ce67fd6493488
https://doi.org/10.1201/9780429263781-8
https://doi.org/10.1201/9780429263781-8
Publikováno v:
Oncology Letters.
Triple-negative breast cancer (TNBC) lacks the expressions of estrogen receptor-α, progesterone receptor and human epidermal growth factor receptor-2. The treatment options for TNBC include anthracyclin/taxol based conventional chemotherapy and smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ef0a994a72fa7a1f3b17b10f93f025b
https://doi.org/10.3892/ol.2019.10182
https://doi.org/10.3892/ol.2019.10182